SUMMARY A 67 year old man with the myasthenic syndrome associated with small cell bronchogenic carcinoma was treated with a new drug, 4-aminopyridine. The muscle weakness showed marked improvement and electrophysiological examinations demonstrated restoration of neuromuscular transmission.
In the myasthenic syndrome sometimes associated with bronchogenic carcinoma (Eaton-Lambert syndrome) muscular weakness is caused by reduced acetylcholine release from motor nerve terminals (Elmqvist and Lambert, 1968) . Guanidine is a potent drug in this condition (Lambert, 1966) but serious adverse reactions have been reported (Lambert and Howard, 1972; Cherington, 1976; Henriksson et al., 1977) . We have treated a patient suffering from this syndrome with a new drug, 4-aminopyridine (4-AP). This drug powerfully increases neurally evoked transmitter release from motor nerves (Molgo et al., 1975) possibly by acting directly on the calcium channels in the nerve terminal membrane, allowing the inward calcium current during depolarisation of the nerve terminal to become regenerative . The drug has recently been shown to restore neuromuscular transmission in paralysis produced by botulinum toxin in the rat Table) . Ten seconds of maximal voluntary contraction caused a marked (300%) increase of the CMAP amplitude.
The patient was treated with cytostatic drugs and radiotherapy. Because serious toxic effects have been reported on treatment with guanidine, we decided, together with the patient and his relatives, to try the new drug 4-AP in the treatment of his myasthenic syndrome.
Intravenous injection of 23 mg (0.33 mg/kg body weight) 4-AP chloride in several doses over a two hour time period restored the CMAP in a dose-dependent manner (Figure-A,C) until it was almost normal. The decrement of muscle response at low frequency stimulation and the increment at high frequency stimulation were significantly reduced as was the potentiation after maximal voluntary contraction (Figure-C) .
To study whether oral administration of the drug was effective, the electrophysiological parameters described above were followed after repeated oral doses of 10 mg 4-AP chloride. This 1109 4-Aminopyridine-a new drug tested in the treatment of Eaton-Lambert syndrome 14-aminopyridine-sulphate.
During treatment with 4-AP the patient reported increased wakefulness with difficulty in sleeping, and with a dose of 4-AP sulphate of more than 100 mg/day the patient complained of an increased sensitivity to light which disappeared when the dosage was reduced. Neuro-ophthalmological examination and recording of the visually evoked response to pattern reversal were normal. The drug was withdrawn gradually and administration was ended after two and a half weeks. The muscle weakness then reappeared and became even more pronounced than before treatment. Concomitantly, the neurophysiological examination showed a further deterioration of the neuromuscular transmission with lower CMAPs than before treatment (Table) .
Discussion
Our attempt to treat this patient with 4-AP demonstrates that the drug is efficient in the treatment of the myasthenic syndrome. The long-term toxic effects of the drug are so far unknown, which was our main reason for ending the treatment. As 4-AP is a powerful stimulant to the central nervous system (Lemeignan, 1970 (Lemeignan, , 1971 it is possible that the photophobia and increased wakefulness reported by our patient are effects of the drug, although the simultaneous treatment with cytostatic drugs and radiotherapy may be of importance in this connection.
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